COVID-19: EMA Says Guillain-Barré Syndrome Is A Side-Effect Of AZ’s Vaxzevria
But EU Safety Assessment Body Rules Out Link with Menstrual Disorders
Executive Summary
The EU’s pharmacovigilance committee has recommended safety updates for two COVID-19 vaccines, and is keeping its eye on a range of possible side-effects with all four authorized products.
You may also be interested in...
EMA 'Confident' Of New COVID-19 Vaccine Approvals By Year End
The European drugs regulator has given an overview of progress with the assessment of new vaccine candidates, additional and booster vaccines, and the use of vaccines in younger age groups.
COVID-19: EU Assessing Booster Dose Of Pfizer/BioNTech’s Comirnaty
As the debate continues over whether booster vaccines will be required to sustain waning immune responses in the general population, the EU regulator says it should have the results of its assessment of an application for a booster dose of Cominarty in the next few weeks.
EU Heart Condition Warning For COVID-19 Vaccines Comirnaty And Spikevax
All four coronavirus vaccines authorized for marketing in the EU/European Economic Area have had their safety information updated because of various adverse events including myocarditis, pericarditis and capillary leak syndrome.